NCT03369912 is a Phase 2 clinical trial of CSJ148 in HCMV Infection, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT03369912?

NCT03369912 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03369912?

Interventions in NCT03369912: CSJ148, Placebo.

What condition does NCT03369912 study?

NCT03369912 studies HCMV Infection.

Is NCT03369912 still recruiting?

NCT03369912 is currently withdrawn. Last updated 9 October 2018.

Last reviewed 2018-10-09 · How we verify

NCT03369912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

Withdrawn Phase 2 Last updated 9 October 2018

What this trial tests

Phase 2 trial testing CSJ148 in HCMV Infection. Withdrawn.

Timeline

23 October 2018

Primary endpoint
15 November 2022

15 November 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	23 October 2018
Primary completion	15 November 2022
Estimated completion	15 November 2022

Drugs / interventions tested

CSJ148 — full drug profile →
Placebo

Conditions studied

HCMV Infection — all drugs for HCMV Infection →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, female only, with HCMV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the feasibility of using CSJ148 to prevent congenital human cytomegalovirus (HCMV) in pregnant women with primary HCMV infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CSJ148

Trials testing the same drug.

NCT02268526 — Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients · Phase 2 · completed

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03369912 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 9 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03369912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing